Page last updated: 2024-11-04

vorinostat and Anemia, Refractory, with Excess of Blasts

vorinostat has been researched along with Anemia, Refractory, with Excess of Blasts in 1 studies

Vorinostat: A hydroxamic acid and anilide derivative that acts as a HISTONE DEACETYLASE inhibitor. It is used in the treatment of CUTANEOUS T-CELL LYMPHOMA and SEZARY SYNDROME.
vorinostat : A dicarboxylic acid diamide comprising suberic (octanedioic) acid coupled to aniline and hydroxylamine. A histone deacetylase inhibitor, it is marketed under the name Zolinza for the treatment of cutaneous T cell lymphoma (CTCL).

Anemia, Refractory, with Excess of Blasts: Chronic refractory anemia with granulocytopenia, and/or thrombocytopenia. Myeloblasts and progranulocytes constitute 5 to 40 percent of the nucleated marrow cells.

Research Excerpts

ExcerptRelevanceReference
"This phase I study was conducted to identify the maximum-tolerated dose (MTD) of alvocidib when combined with vorinostat in patients with relapsed, refractory, or poor prognosis acute leukemia, or refractory anemia with excess blasts-2."9.17A phase I trial of vorinostat and alvocidib in patients with relapsed, refractory, or poor prognosis acute leukemia, or refractory anemia with excess blasts-2. ( Ames, MM; Doyle, A; Grant, S; Holkova, B; Honeycutt, C; Kmieciak, M; McGovern, RM; Perkins, EB; Ramakrishnan, V; Reid, JM; Roberts, JD; Sankala, H; Shapiro, GI; Shrader, E; Supko, JG; Tombes, MB; Wellons, MD; Wright, J, 2013)
"This phase I study was conducted to identify the maximum-tolerated dose (MTD) of alvocidib when combined with vorinostat in patients with relapsed, refractory, or poor prognosis acute leukemia, or refractory anemia with excess blasts-2."5.17A phase I trial of vorinostat and alvocidib in patients with relapsed, refractory, or poor prognosis acute leukemia, or refractory anemia with excess blasts-2. ( Ames, MM; Doyle, A; Grant, S; Holkova, B; Honeycutt, C; Kmieciak, M; McGovern, RM; Perkins, EB; Ramakrishnan, V; Reid, JM; Roberts, JD; Sankala, H; Shapiro, GI; Shrader, E; Supko, JG; Tombes, MB; Wellons, MD; Wright, J, 2013)

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's1 (100.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Holkova, B1
Supko, JG1
Ames, MM1
Reid, JM1
Shapiro, GI1
Perkins, EB1
Ramakrishnan, V1
Tombes, MB1
Honeycutt, C1
McGovern, RM1
Kmieciak, M1
Shrader, E1
Wellons, MD1
Sankala, H1
Doyle, A1
Wright, J1
Roberts, JD1
Grant, S1

Trials

1 trial available for vorinostat and Anemia, Refractory, with Excess of Blasts

ArticleYear
A phase I trial of vorinostat and alvocidib in patients with relapsed, refractory, or poor prognosis acute leukemia, or refractory anemia with excess blasts-2.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2013, Apr-01, Volume: 19, Issue:7

    Topics: Acute Disease; Adult; Aged; Anemia, Refractory, with Excess of Blasts; Antineoplastic Combined Chemo

2013